Page 1 of 1

After five years of rapid and high-quality development

Posted: Mon Jan 20, 2025 6:56 am
by shoponhossaiastu
Connaught has established three major R&D centers around the world, fully mastering core technologies such as mechanical architecture, electrical architecture, software architecture, complex algorithms and visual imaging, and independently building the underlying technology of surgical robots. platform; and has a mass production factory of over 10,000 square meters in the Greater Bay Area, successfully realizing " independent research and development and independent manufacturing " of surgical robots . 2024 is the first year of commercialization for Connustron. The company's independently developed SentireĀ® endoscopic surgical robot was officially approved for marketing by the China National Medical Products Administration (NMPA) on September 29, 2024.

Relying on the high-quality performance and cost advantages of thailand whatsapp mobile phone number list independent research and development and independent manufacturing, Conosten has cooperated with top medical centers in mainland China, Hong Kong, and Europe, and has successfully completed clinical cases in multiple important specialties as planned, which is In the future, the company will expand the international market and serve global medical care, laying a solid foundation for high-quality development.

On the other hand, ConoStation is also actively exploring more application scenarios and clinical cooperation opportunities around the world, accelerating the application popularization of technology and services. By cooperating with medical institutions and educational institutions, the company has made great achievements in the implementation of application and skills training. Made solid progress. At the same time, clinical feedback and the team's research and development of innovative technologies form a virtuous circle, allowing robots to integrate with artificial intelligence to complete more precise and complex surgeries, allowing technological development to promote the popularization of smart medical care and better serve society and the public.

Professor Ou Guowei, founder and CEO of Connaught, said: " 2024 is an important milestone in the development of Connaught. I would like to thank the new and old shareholders for their trust and support of Connaught. This is not only for us. The team's high recognition of the implementation of innovative results is also a firm trust in the company's long-term and high-quality development.